1-year extended adjuvant therapy in a patient with HER2- and HR-positive breast cancer without pCR after surgery
08 Feb 2025
byProf. Kai Li, Specialist in Oncology, Department of Breast Oncology, Shengjing Hospital of China Medical University, China
A 45-year-old premenopausal female who was otherwise healthy presented in September 2020 with a lump, which was the size of an egg yolk, in her right breast. Diagnostic workup revealed multiple irregularly edged masses in the right breast, with the largest located in the upper outer quadrant measuring approximately 37 x 21 mm, and multiple enhanced lymph nodes (LNs) of approximately 13 x 10 mm in the right armpit. Biopsy of the breast mass and LNs showed invasive HER2-positive and hormone receptor (HR)–positive (both oestrogen receptor– and progesterone receptor–positive) ductal carcinoma, with a Ki-67 level of 20 percent. The patient was diagnosed with HER2-positive breast cancer (BC; cT2NxM0).
